COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?
COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?
复制标题
DOI：
10.3332/ecancer.2020.1023
复制
发表时间：
2020-03-30
影响因子：
1.8
通讯作者：
Van Hemelrijck, Mieke
中科院分区：
文献类型：
--
作者：
Russell, Beth;Moss, Charlotte;Van Hemelrijck, Mieke
鉴于目前的SARS-CoV-2(新冠肺炎)大流行，为临床医生和患者提供可靠的信息至关重要。已有多份报告指出，非类固醇抗炎药(NSAID)和皮质类固醇可能会加剧新冠肺炎患者的症状。因此，这篇综述旨在整理已发表文章中的信息，以确定这些说法背后的任何证据，目的是建议临床医生如何最好地治疗患者。这项综述没有发现支持或反对在新冠肺炎患者中使用非类固醇抗炎药的已发表证据。与此同时，似乎有一些证据表明，如果在感染的早期急性阶段使用皮质类固醇可能是有益的，然而，世界卫生组织关于某些病毒感染中使用皮质类固醇的相互矛盾的证据意味着，这一证据并不是决定性的。鉴于目前文献的可用性，在有更多证据显示新冠肺炎患者使用非甾体抗炎药和皮质类固醇之前，应谨慎行事。
Given the current SARS-CoV-2 (COVID-19) pandemic, the availability of reliable information for clinicians and patients is paramount. There have been a number of reports stating that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. Therefore, this review aimed to collate information available in published articles to identify any evidence behind these claims with the aim of advising clinicians on how best to treat patients. This review found no published evidence for or against the use of NSAIDs in COVID-19 patients. Meanwhile, there appeared to be some evidence that corticosteroids may be beneficial if utilised in the early acute phase of infection, however, conflicting evidence from the World Health Organisation surrounding corticosteroid use in certain viral infections means this evidence is not conclusive. Given the current availability of literature, caution should be exercised until further evidence emerges surrounding the use of NSAIDs and corticosteroids in COVID-19 patients.